Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Manuella Bouttier is active.

Publication


Featured researches published by Manuella Bouttier.


Blood | 2008

Transcriptional repression of microRNA genes by PML-RARA increases expression of key cancer proteins in acute promyelocytic leukemia

Anne Saumet; Guillaume Vetter; Manuella Bouttier; Elodie Portales-Casamar; Wyeth W. Wasserman; Thomas Maurin; Bernard Mari; Pascal Barbry; Laurent Vallar; Evelyne Friederich; Khalil Arar; Bruno Cassinat; Christine Chomienne; Charles-Henri Lecellier

Micro(mi)RNAs are small noncoding RNAs that orchestrate many key aspects of cell physiology and their deregulation is often linked to distinct diseases including cancer. Here, we studied the contribution of miRNAs in a well-characterized human myeloid leukemia, acute promyelocytic leukemia (APL), targeted by retinoic acid and trioxide arsenic therapy. We identified several miRNAs transcriptionally repressed by the APL-associated PML-RAR oncogene which are released after treatment with all-trans retinoic acid. These coregulated miRNAs were found to control, in a coordinated manner, crucial pathways linked to leukemogenesis, such as HOX proteins and cell adhesion molecules whose expressions are thereby repressed by the chemotherapy. Thus, APL appears linked to transcriptional perturbation of miRNA genes, and clinical protocols able to successfully eradicate cancer cells may do so by restoring miRNA expression. The identification of abnormal miRNA biogenesis in cancer may therefore provide novel biomarkers and therapeutic targets in myeloid leukemias.


Blood | 2009

HTLV-1 uses HSPG and neuropilin-1 for entry by molecular mimicry of VEGF165

Sophie Lambert; Manuella Bouttier; Roger Vassy; Michel Seigneuret; Cari Petrow-Sadowski; Sébastien Janvier; Nikolaus Heveker; Francis W. Ruscetti; Gérard Y Perret; Kathryn S. Jones; Claudine Pique

Human T-cell lymphotropic virus type 1 (HTLV-1) entry involves the interaction between the surface (SU) subunit of the Env proteins and cellular receptor(s). Previously, our laboratories demonstrated that heparan sulfate proteoglycans (HSPGs) and neuropilin-1 (NRP-1), a receptor of VEGF(165), are essential for HTLV-1 entry. Here we investigated whether, as when binding VEGF(165), HSPGs and NRP-1 work in concert during HTLV-1 entry. VEGF(165) binds to the b domain of NRP-1 through both HSPG-dependent and -independent interactions, the latter involving its exon 8. We show that VEGF(165) is a selective competitor of HTLV-1 entry and that HTLV-1 mimics VEGF(165) to recruit HSPGs and NRP-1: (1) the NRP-1 b domain is required for HTLV-1 binding; (2) SU binding to target cells is blocked by the HSPG-binding domain of VEGF(165); (3) the formation of Env/NRP-1 complexes is enhanced by HSPGs; and (4) the HTLV SU contains a motif homologous to VEGF(165) exon 8. This motif directly binds to NRP-1 and is essential for HTLV-1 binding to, internalization into, and infection of CD4(+) T cells and dendritic cells. These findings demonstrate that HSPGs and NRP-1 function as HTLV-1 receptors in a cooperative manner and reveal an unexpected mimicry mechanism that may have major implications in vivo.


Nucleic Acids Research | 2012

Retroviral GAG proteins recruit AGO2 on viral RNAs without affecting RNA accumulation and translation

Manuella Bouttier; Anne Saumet; Marion Peter; Valérie Courgnaud; Ute Schmidt; Chantal Cazevieille; Edouard Bertrand; Charles-Henri Lecellier

Cellular micro(mi)RNAs are able to recognize viral RNAs through imperfect micro-homologies. Similar to the miRNA-mediated repression of cellular translation, this recognition is thought to tether the RNAi machinery, in particular Argonaute 2 (AGO2) on viral messengers and eventually to modulate virus replication. Here, we unveil another pathway by which AGO2 can interact with retroviral mRNAs. We show that AGO2 interacts with the retroviral Group Specific Antigen (GAG) core proteins and preferentially binds unspliced RNAs through the RNA packaging sequences without affecting RNA stability or eliciting translation repression. Using RNAi experiments, we provide evidences that these interactions, observed with both the human immunodeficiency virus 1 (HIV-1) and the primate foamy virus 1 (PFV-1), are required for retroviral replication. Taken together, our results place AGO2 at the core of the retroviral life cycle and reveal original AGO2 functions that are not related to miRNAs and translation repression.


Molecular BioSystems | 2012

Estrogen and retinoic acid antagonistically regulate several microRNA genes to control aerobic glycolysis in breast cancer cells

Anne Saumet; Guillaume Vetter; Manuella Bouttier; Etienne Antoine; Christine Roubert; Béatrice Orsetti; Charles Theillet; Charles-Henri Lecellier

In addition to estrogen receptor modulators, retinoic acid and other retinoids are promising agents to prevent breast cancer. Retinoic acid and estrogen exert antagonistic regulations on the transcription of coding genes and we evaluated here whether these two compounds have similar effects on microRNAs. Using an integrative approach based on several bioinformatics resources together with experimental validations, we indeed found that retinoic acid positively regulates miR-210 and miR-23a/24-2 expressions and is counteracted by estrogen. Conversely, estrogen increased miR-17/92 and miR-424/450b expressions and is inhibited by retinoic acid. In silico functional enrichment further revealed that this combination of transcriptional/post-transcriptional regulations fully impacts on the molecular effects of estrogen and retinoic acid. Besides, we unveiled a novel effect of retinoic acid on aerobic glycolysis. We specifically showed that it increases extracellular lactate production, an effect counteracted by the miR-210 and the miR-23a/24-2, which simultaneously target lactate dehydrogenase A and B mRNAs. Together our results provide a new framework to better understand the estrogen/retinoic acid antagonism in breast cancer cells.


Biomolecular Concepts | 2013

RNAi and retroviruses: are they in RISC?

Thierry Vasselon; Manuella Bouttier; Anne Saumet; Charles-Henri Lecellier

Abstract RNA interference (RNAi) is a potent cellular system against viruses in various organisms. Although common traits are observed in plants, insects, and nematodes, the situation observed in mammals appears more complex. In mammalian somatic cells, RNAi is implicated in endonucleolytic cleavage mediated by artificially delivered small interfering RNAs (siRNAs) as well as in translation repression mediated by microRNAs (miRNAs). Because siRNAs and miRNAs recognize viral mRNAs, RNAi inherently limits virus production and participates in antiviral defense. However, several observations made in the cases of hepatitis C virus and retroviruses (including the human immunodeficiency virus and the primate foamy virus) bring evidence that this relationship is much more complex and that certain components of the RNAi effector complex [called the RNA-induced silencing complex (RISC)], such as AGO2, are also required for viral replication. Here, we summarize recent discoveries that have revealed this dual implication in virus biology. We further discuss their potential implications for the functions of RNAi-related proteins, with special emphasis on retrotransposition and genome stability.


Archive | 2008

microRNA-Associated Therapies

Anne Saumet; Guillaume Vetter; Nicolas Cougot; Manuella Bouttier; Florence Rage; Khalil Arar; Charles-Henri Lecellier


Archive | 2013

expression of key cancer proteins in acute promyelocytic leukemia Transcriptional repression of microRNA genes by PML-RARA increases

Christine Chomienne; Charles-Henri Lecellier; Thomas Maurin; Bernard Mari; Pascal Barbry; Laurent Vallar; Evelyne Friederich; Khalil Arar; Anne Saumet; Guillaume Vetter; Manuella Bouttier; Elodie Portales-Casamar; Wyeth W. Wasserman


Archive | 2013

165 VEGF HTLV-1 uses HSPG and neuropilin-1 for entry by molecular mimicry of

Claudine Pique; Sébastien Janvier; Nikolaus Heveker; Francis W. Ruscetti; Gérard Y Perret; Kathryn S. Jones; Sophie Lambert; Manuella Bouttier; Roger Vassy; Michel Seigneuret; Cari Petrow-Sadowski


Virologie | 2012

Les récepteurs d’entrée du HTLV-1 : un ménage à trois

Sophie Lambert; Manuella Bouttier; David Ghez; Oliver Hermine; Claudine Pique


Archive | 2010

Identifizierung von virus tropismus

Charles-Henri Lecellier; Valérie Courgnaud; Manuella Bouttier; Diane Descamps; Gilles Collin

Collaboration


Dive into the Manuella Bouttier's collaboration.

Top Co-Authors

Avatar

Charles-Henri Lecellier

Centre national de la recherche scientifique

View shared research outputs
Top Co-Authors

Avatar

Anne Saumet

University of Montpellier

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Claudine Pique

Centre national de la recherche scientifique

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Thomas Maurin

University of Nice Sophia Antipolis

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge